Improving Aspirin Prescription Rates in Outpatient Clinic

NCT06694233 | Terminated

• 1 other identifier: QIP1
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Ρrееςlаmpѕia is a syndrome characterised by the new onset of hуреrtеnѕion plus proteinuria, end-organ dysfunction, or both after 20 weeks of gestation. It complicates 3-5% of pregnancies. Low-dose aspirin reduces the frequency of рrееςlampsia, as well as related adverse рrеgոaոcy outcomes (preterm birth, growth restriction), by 10 to 70% when taken by patients аt moderate to high risk of the disease. It has an excellent maternal/fetal safety profile. Thus, it is a reasonable preventive strategy for these patients. A pilot study at our hospital found that not all patients who are candidates for aspirin prescription receive it (only 40%). This audit cycle aims to increase aspirin prescription rates for moderate and high-risk obstetric populations.

Conditions

Low Birth Weight; Small for Gestational Age (SGA); Preeclampsia (PE); Prevention &Amp; Control

Keywords

Aspirin; Preeclampsia; obstetric; risk population

Outcome Measures

Primary Outcomes (1)

• Aspirin prescription

  Six months

Study Arms (1)

Obstetric population candidate for aspirin prescription

Moderate- and high-risk obstetric population

Other: Aspirin prescription on outpatient basis

Interventions

Aspirin prescription on outpatient basis OTHER

Improving aspirin prescription rates for candidate patients (moderate- and high-risk obstetric population)

Obstetric population candidate for aspirin prescription

Eligibility Criteria

• Gender Eligibility Details: Obstetric population
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Moderate- and high- risk obstetric population

You may qualify if:

• Women at high risk are those with any of the following:
• hypertensive disease during a previous pregnancy
• chronic kidney disease
• autoimmune disease such as systemic lupus erythematosus or antiphospholipid syndrome
• type 1 or type 2 diabetes
• chronic hypertension.
• Women with more than one moderate risk factor, such as are:
• nulliparity
• age 40 years or older
• pregnancy interval of more than 10 years
• body mass index (BMI) of 35 kg/m2 or more at first visit
• family history of pre-eclampsia
• multi-fetal pregnancy.

You may not qualify if:

• None. All eligible candidates will be included.

Sponsors & Collaborators

• Cairo University: lead

Study Sites (1)

Adan hospital

Al Ahmadi, Al Ahmadi, 47000, Kuwait

Location

Related Publications (2)

• Singh N, Shuman S, Chiofalo J, Cabrera M, Smith A. Missed opportunities in aspirin prescribing for preeclampsia prevention. BMC Pregnancy Childbirth. 2023 Oct 7;23(1):717. doi: 10.1186/s12884-023-06039-w.

  PMID: 37805449 BACKGROUND

• Kumar NR, Speedy SE, Song J, Welty LJ, Cavens AD. Quality Improvement Initiative for Aspirin Screening and Prescription Rates for Preeclampsia Prevention in an Outpatient Obstetric Clinic. Am J Perinatol. 2024 May;41(S 01):e917-e921. doi: 10.1055/s-0042-1759705. Epub 2022 Dec 30.

  PMID: 36584691 BACKGROUND

Related Links

• Related Info

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr

Study Record Dates

• First Submitted: November 14, 2024
• First Posted: November 19, 2024
• Study Start: November 1, 2024
• Primary Completion: April 30, 2025
• Study Completion: April 30, 2025
• Last Updated: July 10, 2025

Record last verified: 2025-07

Locations

KU (1)